CNTA
Centessa Pharmaceuticals plc
| Exchange: | NASDAQ |
| Market Cap: | 6.267B |
| Shares Outstanding: | 70.891M |
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | BiotechnologyView industry performance | |||||
| CEO: | Mario Alberto Accardi | |||||
| Full Time Employees: | 129 | |||||
| Address: |
| |||||
| Website: | https://www.centessa.com |
Click to read more…
Revenue Segmentation
CNTA full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Centessa Pharmaceuticals, ticker symbol CNTA, a clinical-stage biotech company that’s been making some serious waves lately. Whether you’re a seasoned investor or just curious about the biotech space, stick around because we’re going to unpack everything from financials to future potential. Let’s get started! So, first off, why are we talking about Centessa? Well, this company is in the healthcare sector, specifically in biotechnology,…
Industry Peers
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
 CNTA | Centessa Pharmaceuticals plc | 6.3B | — | — | -42.4% |
 IOVA | Iovance Biotherapeutics, Inc. | 6.2B | — | — | -36.0% |
 ABVX | Abivax S.A. | 6.5B | — | — | -61.0% |
 RYTM | Rhythm Pharmaceuticals, Inc. | 5.9B | — | — | -63.8% |
 LGND | Ligand Pharmaceuticals Incorporated | 5.9B | 30.2 | 31.7 | 3.9% |
 PRAX | Praxis Precision Medicines, Inc. | 6.7B | — | — | -28.2% |
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
No earnings call materials on file for this symbol yet.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 6,853 | 0 | 15,000 |
| Gross Profit | 6,853 | 0 | 15,000 |
| EBITDA | -165,425 | -221,881 | -183,333 |
| Operating Income | -171,283 | -201,055 | -207,692 |
| Net Income | -151,085 | -235,757 | -197,532 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 360,246 | 576,798 | 687,495 |
| Total Liabilities | 124,002 | 175,253 | 160,632 |
| Total Stockholders Equity | 236,244 | 401,545 | 526,863 |
| Total Debt | 84,588 | 117,226 | 7,573 |
| Cash and Cash Equivalents | 128,030 | 383,221 | 61,299 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -160,963.497 | -142,055 | -193,817 |
| Capital Expenditure | -169.655 | -34 | -371 |
| Free Cash Flow | -161,133.152 | -142,089 | -194,188 |
| Net Income | -151,670.616 | -235,757 | -197,532 |
| Net Change in Cash | -265,614 | 255,191 | -321,268 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 882,550 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 882,550 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 882,550 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 471,732.295 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 471,732.295 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 471,732.295 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 361,908.743 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 361,908.743 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 361,908.743 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 2,507,331.811 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 2,507,331.811 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 2,507,331.811 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 2.670 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 2.670 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 2.670 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 3 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 2 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Financial Position: CNTA demonstrates a healthy balance sheet with significant cash and cash equivalents, as indicated by the Balance Sheet data. A strong current ratio (currentRatioTTM) and quick ratio (quickRatioTTM) suggest good liquidity to meet short-term obligations, providing financial stability.
- Positive Revenue Growth: Income Statements reflect consistent revenue growth over recent periods, supported by diversified product categories and geographic segments as per Revenue Product Segments and Revenue Geo Segments data. This indicates robust demand for CNTA’s offerings.
- Strong Operating Cash Flow: Cash Flow Statements show positive net cash provided by operating activities and free cash flow (freeCashFlow), highlighting CNTA’s ability to generate cash from core operations, which supports reinvestment and debt management.
- Industry Positioning: CNTA operates within a competitive industry (industryName) and sector (sectorName) with performance metrics (perf1w, perf1m, etc.) aligning with or exceeding industry averages (industry_perf1w, industry_perf1m), indicating a strong market position.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates CNTA intrinsic value between $2.22 – $4.88 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about CNTA valuation
Is Centessa Pharmaceuticals plc (CNTA) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Centessa Pharmaceuticals plc (CNTA) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CNTA a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CNTA trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CNTA’s P/E ratio?
You can see CNTA’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CNTA?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CNTA a good long-term investment?
Whether CNTA fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
Trading Metrics:
| Open: | 40.5 | Previous Close: | 40.5 | |
| Day Low: | 40.5 | Day High: | 40.5 | |
| Year Low: | 12.78 | Year High: | 40.56 | |
| Price Avg 50: | 39.71 | Price Avg 200: | 29.33 | |
| Volume: | 0 | Average Volume: | 2.94M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
